Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04556890 · ClinicalTrials.gov registry record · NA
Pain and Major Depressive Disorder
A NA study of Chronic Pain and Major Depressive Disorder, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04556890: Recruiting NA study of Chronic Pain and Major Depressive Disorder, sponsored by University of California, Los Angeles.
NCT04556890 is a NA study of Chronic Pain and Major Depressive Disorder that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 54 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04556890, a NA study of Chronic Pain and Major Depressive Disorder, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits and volunteer 40 hours of their time. Compensation for this study is $150 for completing all study activities.
Primary Outcome
Inventory of Depressive symptoms- Self (IDS-SR) scores will be analyzed as the primary outcome measure. The IDS-SR is a 30-item scale that measures various symptoms of depression. Each item is scored between 0-4. Severity of depression is associated with a higher score with scores ranging from 0 to 84.
Conditions Studied
Interventions
- DEVICE Active rTMS/Active iTBS DFPLC/Sham Pain M1
- DEVICE Active rTMS/Active iTBS
Study Locations (1)
California
- UCLA Semel Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2027-10-31 |
| Phase | NA |
What NCT04556890 shows while recruiting
NCT04556890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Active rTMS/Active iTBS DFPLC/Sham Pain M1 is the first listed.
NCT04556890 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04556890 about?
NCT04556890 is a clinical study titled "Pain and Major Depressive Disorder". This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 tr...
What is the current status of trial NCT04556890?
This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2023-03-01. Estimated completion is 2027-10-31.
What conditions does trial NCT04556890 study?
This clinical trial studies the following conditions: Chronic Pain, Major Depressive Disorder.
What interventions are being tested in trial NCT04556890?
The interventions under investigation include: Active rTMS/Active iTBS DFPLC/Sham Pain M1 (DEVICE), Active rTMS/Active iTBS (DEVICE).
Who is sponsoring clinical trial NCT04556890?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04556890 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04556890's enrollment target sits among peer trials
54 193rd of 301 higher than 109 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
RECRUITING · NA
-
Local Cerebral Oxygenation in Chronic Pain Patients Utilizing Spinal Cord Stimulation
RECRUITING · NA
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma
RECRUITING · NA
-
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
RECRUITING · NA
-
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI